EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company’s ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes’ pipeline after NCT advancing towards partnership and commercialization. Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company’s platform LOS ANGELES, CA - June 24, 2026 - eXoZymes Inc. (NASDAQ: EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals - today announced that it has received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518. The NIH funded work is expected to begin July 1, 2026, and will support eXoZym…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
eXoZymes Inc.
EXOZNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On June 24, 2026, the Company issued a press release announcing that it was being awarded a $2 Million NIH grant to advance cannaboinoid analogs for drug discovery.…
Company context
Current securities
Historical securities (1)
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On
June 24, 2026, the Company issued a press release announcing that it was being awarded a $2 Million NIH grant to advance cannaboinoid
analogs for drug discovery.
The
information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act, or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.